BACKGROUND: Assays measuring thrombin generation (TG) in plasma increasingly gained attention in the field of thrombosis and hemostasis. Adaptation of the method enabled the measurement of TG in whole blood (WB). Despite their potential, TG assays did not reach the stage of universal clinical application, partly because of the absence of normal ranges. Our study aimed to accurately determine normal ranges and interindividual variability of TG and correlate results with coagulation factor levels, sex, and oral contraceptive usage. METHODS: The study protocol was evaluated by the local medical ethical board. In total, 129 healthy volunteers gave full informed consent. Normal ranges of TG in platelet-poor plasma (PPP), platelet-rich plasma (PRP), and WB were determined according to CLSI guidelines. RESULTS: Our study is the first to measure normal ranges of TG in PPP, PRP, and WB in a large healthy cohort. Significant correlations were found between TG in plasma and WB. Interindividual variability of TG in WB was comparable to that of plasma. Oral contraceptive use increased TG in PPP, PRP, and WB. The inhibitory effect of thrombomodulin on TG was significantly lower in females than in males. This effect was more pronounced upon oral contraceptive use. Primary clotting factor determinants for TG parameters depended on the tissue factor concentration, but were similar in WB and plasma. CONCLUSIONS: Establishing normal ranges for TG brings us 1 step closer to clinical use. Good correlations between plasma and WB (including clotting factor determinants for TG) suggest that WB TG can be reliably used in clinic.
BACKGROUND: Assays measuring thrombin generation (TG) in plasma increasingly gained attention in the field of thrombosis and hemostasis. Adaptation of the method enabled the measurement of TG in whole blood (WB). Despite their potential, TG assays did not reach the stage of universal clinical application, partly because of the absence of normal ranges. Our study aimed to accurately determine normal ranges and interindividual variability of TG and correlate results with coagulation factor levels, sex, and oral contraceptive usage. METHODS: The study protocol was evaluated by the local medical ethical board. In total, 129 healthy volunteers gave full informed consent. Normal ranges of TG in platelet-poor plasma (PPP), platelet-rich plasma (PRP), and WB were determined according to CLSI guidelines. RESULTS: Our study is the first to measure normal ranges of TG in PPP, PRP, and WB in a large healthy cohort. Significant correlations were found between TG in plasma and WB. Interindividual variability of TG in WB was comparable to that of plasma. Oral contraceptive use increased TG in PPP, PRP, and WB. The inhibitory effect of thrombomodulin on TG was significantly lower in females than in males. This effect was more pronounced upon oral contraceptive use. Primary clotting factor determinants for TG parameters depended on the tissue factor concentration, but were similar in WB and plasma. CONCLUSIONS: Establishing normal ranges for TG brings us 1 step closer to clinical use. Good correlations between plasma and WB (including clotting factor determinants for TG) suggest that WB TG can be reliably used in clinic.
Authors: Reed W Kamyszek; Matthew W Foster; Brooke A Evans; Keaton Stoner; Jessica Poisson; Amudan J Srinivasan; J Will Thompson; M Arthur Moseley; Micah J Mooberry; Ian J Welsby Journal: Blood Transfus Date: 2020-08-06 Impact factor: 3.443
Authors: Li Li; Mark Roest; Yaqiu Sang; Jasper A Remijn; Rob Fijnheer; Karel Smit; Dana Huskens; Jun Wan; Bas de Laat; Joke Konings Journal: Front Cardiovasc Med Date: 2022-06-27
Authors: Jun Wan; Nadira Vadaq; Joke Konings; Martin Jaeger; Vinod Kumar; Bas de Laat; Leo Joosten; Mihai G Netea; Andre J van der Ven; Philip G de Groot; Quirijn de Mast; Mark Roest Journal: J Thromb Haemost Date: 2021-09-28 Impact factor: 16.036
Authors: Romy de Laat-Kremers; Augusto Di Castelnuovo; Lisa van der Vorm; Simona Costanzo; Marisa Ninivaggi; Chiara Cerletti; Dana Huskens; Amalia De Curtis; Alessandro Gialluisi; Cuicui Bai; Giovanni de Gaetano; Dongmei Yin; Maria Benedetta Donati; Bas de Laat; Licia Iacoviello Journal: Front Cardiovasc Med Date: 2022-06-16
Authors: Adam Miszta; Anna K Kopec; Asmita Pant; Lori A Holle; James R Byrnes; Daniel A Lawrence; Kirk C Hansen; Matthew J Flick; James P Luyendyk; Bas de Laat; Alisa S Wolberg Journal: Blood Date: 2020-05-07 Impact factor: 22.113
Authors: Abdulrahman B O Mohamed; Nabeel Al-Ama; Huda Al Kreathy; Khalid H B Ahmed; Turki Al Amri; Steve Harakeh; Shaker A Mousa; Bas De Laat Journal: Clin Appl Thromb Hemost Date: 2020 Jan-Dec Impact factor: 2.389
Authors: Godfrey S Temba; Nadira Vadaq; Jun Wan; Vesla Kullaya; Dana Huskens; Tal Pecht; Martin Jaeger; Collins K Boahen; Vasiliki Matzaraki; Wieteke Broeders; Leo A B Joosten; Sultana M H Faradz; Gibson Kibiki; Saskia Middeldorp; Duccio Cavalieri; Paolo Lionetti; Philip G de Groot; Joachim L Schultze; Mihai G Netea; Vinod Kumar; Bas de Laat; Blandina T Mmbaga; Andre J van der Ven; Mark Roest; Quirijn de Mast Journal: J Thromb Haemost Date: 2022-02-10 Impact factor: 16.036